Pancreatic Cancer Research

ResearcherNorthwell HealthActive in the last 2 years

Oliver J. Standring

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-4912-6195; OpenAlex author ID A5050133619. Sources: OpenAlex.

Their work

Papers
12 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: 4 papers · 2025: 4 papers · 2026: 2 papers

Papers 12

  1. Medicaid Expansion Timing and Pancreatic Cancer Resection Rates and Survival. Co-author DOI 10.1001/jamasurg.2026.0057↗
  2. Implantable Microdevices for In Vivo Assessment of Chemotherapy Response in Patient Derived Organoid Orthotopic Pancreatic Cancer Models. Co-author DOI 10.1097/sla.0000000000007071↗
  3. Evaluating the Association of Area Deprivation Index (ADI) on Postoperative Outcomes in Pancreatic Adenocarcinoma. Co-author DOI 10.1002/jso.27996↗
  4. Trends and Outcomes of Neoadjuvant Chemotherapy for Clinical Stage T1 Pancreatic Cancer. First author DOI 10.1002/jso.28003↗
  5. Impact of Environmental Quality on Pancreatic Cancer Outcomes Post Pancreatoduodenectomy: A Retrospective Cohort Study. Co-author DOI 10.1007/s12029-025-01254-4↗
  6. Management of Peritoneal Metastasis in Patients with Pancreatic Ductal Adenocarcinoma. First author DOI 10.3390/curroncol32020103↗
  7. Modified 5-Item Frailty Index (mFI-5) may predict postoperative outcomes after pancreatoduodenectomy for pancreatic Cancer. Co-author DOI 10.1007/s00423-024-03483-w↗
  8. Comparison of neoadjuvant chemotherapy plus radiation vs. chemotherapy alone on complete pathologic response in pancreatic adenocarcinoma: an analysis of the n… Co-author DOI 10.1007/s44337-024-00145-0↗
  9. Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting. First author DOI 10.1245/s10434-024-15352-3↗
  10. ASO Author Reflections: Identifying and Understanding How Vulnerable Populations Are Affected by Delays in Pancreatic Cancer Care. First author DOI 10.1245/s10434-024-15476-6↗
  11. Development of a Neoadjuvant Treatment Pathway to Standardize Pancreatic Cancer Care and Improve Outcomes Across a Large Diverse Health System Co-author DOI 10.1101/2023.09.19.23295749↗
  12. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy. Co-author DOI 10.1097/sla.0000000000005558↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Danielle K. DePeralta · 10 shared papers, 2022–2026 · strength 2.19
  2. Daniel A. King · 10 shared papers, 2022–2026 · strength 2.11
  3. Lyudmyla Demyan · 9 shared papers, 2022–2026 · strength 1.78
  4. Sepideh Gholami · 6 shared papers, 2024–2026 · strength 1.47
  5. Matthew John Weiss · 7 shared papers, 2022–2025 · strength 1.34
  6. Shamsher Ali Pasha · 7 shared papers, 2022–2025 · strength 1.33
  7. Gary Deutsch · 5 shared papers, 2022–2025 · strength 0.96
  8. Joseph M. Herman · 5 shared papers, 2022–2024 · strength 0.85
  9. Marcovalerio Melis · 3 shared papers, 2024–2025 · strength 0.69
  10. Matthew John Weiss · 3 shared papers, 2024–2025 · strength 0.69
  11. Elliot Newman · 3 shared papers, 2024–2025 · strength 0.69
  12. Abdullah Khalid · 3 shared papers, 2024–2025 · strength 0.69
  13. Julien T. Hohenleitner · 2 shared papers, 2026 · strength 0.54
  14. Shruti Koti · 2 shared papers, 2025–2026 · strength 0.50
  15. Neha L. Lad · 2 shared papers, 2024–2025 · strength 0.46
  16. Neda Amini · 2 shared papers, 2024–2025 · strength 0.46
  17. John Fallon · 2 shared papers, 2024 · strength 0.38
  18. David Arthur Tuveson · 2 shared papers, 2022–2026 · strength 0.35
  19. M. Weiss · 1 shared paper, 2026 · strength 0.30
  20. Gerardo A. Vitiello · 1 shared paper, 2026 · strength 0.30
  21. Matthew J. Weiss · 1 shared paper, 2026 · strength 0.24
  22. Youngkyu Park · 1 shared paper, 2026 · strength 0.24
  23. Craig Devoe · 1 shared paper, 2025 · strength 0.24
  24. Grace Wu · 1 shared paper, 2025 · strength 0.24
  25. Travis Edward Grotz · 1 shared paper, 2025 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.